{"id":"placebo-for-fp","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inert substances used as control comparators in clinical trials to measure the true efficacy of an investigational drug by accounting for psychological and physiological responses to treatment expectation. In this Phase 3 trial for FP (indication unknown), the placebo arm serves to establish baseline response rates and distinguish genuine drug effects from placebo response.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:12.607Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FP (indication not specified)"}]},"trialDetails":[{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT03675737","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":1579},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00995475","phase":"PHASE4","title":"A Proof of Concept Study to Evaluate the Dose Response for the Systemic Benefit Risk Ratio of Inhaled Fluticasone Propionate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2006-10","conditions":"COPD","enrollment":18},{"nctId":"NCT04111263","phase":"NA","title":"Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude","status":"COMPLETED","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2019-10-06","conditions":"Gastrointestinal Injury, Acute Mountain Sickness","enrollment":33},{"nctId":"NCT00783224","phase":"PHASE3","title":"A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Perennial Allergic Rhinitis","enrollment":351},{"nctId":"NCT04859582","phase":"PHASE3","title":"Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-11-08","conditions":"Stomach Neoplasms","enrollment":""},{"nctId":"NCT02139644","phase":"PHASE3","title":"Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":787},{"nctId":"NCT02141854","phase":"PHASE3","title":"Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-06","conditions":"Asthma","enrollment":882},{"nctId":"NCT02980133","phase":"PHASE3","title":"Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2016-12-28","conditions":"Asthma","enrollment":841},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT03207243","phase":"PHASE2","title":"Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Asthma","enrollment":165},{"nctId":"NCT03894800","phase":"PHASE4","title":"Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-04-23","conditions":"Acute Pain, Trauma, Hypovolemia","enrollment":12},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT03707678","phase":"PHASE2","title":"A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-21","conditions":"Asthma","enrollment":""},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT01916226","phase":"PHASE4","title":"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-01","conditions":"Rhinitis, Allergic, Perennial and Seasonal","enrollment":682},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT01299610","phase":"PHASE2","title":"A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-01","conditions":"Dermatitis, Atopic","enrollment":25},{"nctId":"NCT01479621","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-01","conditions":"Asthma","enrollment":909},{"nctId":"NCT02094937","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-27","conditions":"Asthma","enrollment":430},{"nctId":"NCT01542619","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT01156792","phase":"PHASE2","title":"Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Asthma","enrollment":162},{"nctId":"NCT00929578","phase":"PHASE2","title":"Fluphenazine Hydrochloride for Psoriasis","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2008-11","conditions":"Psoriasis","enrollment":15},{"nctId":"NCT01845025","phase":"PHASE4","title":"Study of Safety of Foradil in Patients With Persistent Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Persistent Asthma","enrollment":827},{"nctId":"NCT01248975","phase":"PHASE2","title":"Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12","conditions":"Asthma","enrollment":145},{"nctId":"NCT01772056","phase":"PHASE3","title":"Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children","status":"TERMINATED","sponsor":"Elena Rubio Gomis","startDate":"2009-12","conditions":"Dermatitis, Atopic","enrollment":54},{"nctId":"NCT01516073","phase":"PHASE2","title":"12-Week Study in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"Asthma","enrollment":629},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for FP","genericName":"Placebo for FP","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is a small molecule intervention used in clinical trials, typically administered as 0.9% normal saline. It has been studied in various conditions, including Chronic Obstructive Pulmonary Disease, Asthma, and Perennial Allergic Rhinitis, as a control in comparison to other interventions such as rVIIa-FP and Fluticasone Propionate/Formoterol Fumarate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}